GGrantIndex
← Search

Epigenomics, RNA and Gene Regulation

$86,973P30FY2020CANIH

University Of California Los Angeles, Los Angeles CA

Investigators

Linked publications, trials & patents

Trial NCT07339085Trial NCT07276438Trial NCT07242365Trial NCT06650163Trial NCT06568016Trial NCT06113016Trial NCT05595499Trial NCT04205838Trial NCT04201873Trial NCT04185311Trial NCT04119024Trial NCT04106362Trial NCT04069923Trial NCT04069910Trial NCT04050215Trial NCT04007029Trial NCT03996850Trial NCT03970252Trial NCT03953157Trial NCT03904251Trial NCT03902951Trial NCT03892720Trial NCT03830918Trial NCT03825796Trial NCT03745690Trial NCT03732950Trial NCT03732352Trial NCT03672773Trial NCT03623854Trial NCT03618134Trial NCT03603223Trial NCT03601455Trial NCT03596710Trial NCT03582774Trial NCT03582475Trial NCT03541850Trial NCT03515577Trial NCT03506802Trial NCT03425461Trial NCT03411070Trial NCT03368547Trial NCT03319342Trial NCT03240861Trial NCT03202472Trial NCT03128619Trial NCT03025139Trial NCT03014804Trial NCT02940262Trial NCT02928510Trial NCT02925351Trial NCT02919332Trial NCT02902757Trial NCT02888301Trial NCT02881242Trial NCT02880020Trial NCT02879994Trial NCT02830165Trial NCT02816879Trial NCT02775292Trial NCT02756130Trial NCT02701153Trial NCT02688348Trial NCT02683200Trial NCT02672033Trial NCT02597894Trial NCT02575027Trial NCT02451865Trial NCT02336763Trial NCT02310594Trial NCT02296229Trial NCT02280161Trial NCT02263898Trial NCT02176902Trial NCT02070406Trial NCT02049593Trial NCT02048020Trial NCT02015559Trial NCT01912820Trial NCT01013285Trial NCT01005472Trial NCT00999557Trial NCT00998010Trial NCT00985192Trial NCT00955591Trial NCT00882765Trial NCT00880542Trial NCT00769470Trial NCT00706615Trial NCT00685516Trial NCT00616642Trial NCT00612066Trial NCT00601289Trial NCT00601094Trial NCT00521209Trial NCT00509431Trial NCT00471887Trial NCT00450567Trial NCT00444223Trial NCT00352001Trial NCT00349167

Abstract

EPIGENOMICS, RNA, AND GENE REGULATION RESEARCH PROGRAM (ERGR) ABSTRACT The Epigenomics, RNA, and Gene Regulation Research Program (ERGR), led by Michael Carey, PhD (Program Director) and Siavash Kurdistani, MD (Program Co-Director), is the most basic of the JCCC Research Programs. Program objectives are to support exceptional JCCC researchers and teams, to ensure ongoing Program robustness with strategic recruitments and training, and to innovate breakthroughs in gene regulation, RNA biology, and bioinformatics with impact in cancer. The expectation is that ERGR investigator discoveries will uncover vulnerabilities for targeting by novel diagnostic and anti-tumor treatment strategies. ERGR investigators employ a range of model systems, from yeast and plants to cancer cells and small animals, to elucidate mechanisms of gene regulation, from chromatin and transcription to RNA biology, to understand and dissect alterations in cancer. Program studies extend to physiological and pathological processes implicated in cancer including cell differentiation, inflammation, and lipid metabolism. ERGR leads in developing new technologies and methodologies, such as advanced informatics for high-throughput experimental tools, and provides expertise to researchers in all six JCCC Research Programs. Although focused on epigenomics and gene regulatory mechanisms, ERGR strives to translate new knowledge to preclinical and clinical settings, with Program discoveries underpinning clinical HDAC inhibitor development and cell free DNA diagnostics. The ERGR Research Program has 33 members drawn from five UCLA schools and partner institution, Caltech, representing 13 departments. As of March 1, 2019, Program support was $11,256,579 in direct cost funding, of which $9,904,290 (88%) is peer-reviewed, and $1,031,199 (9%) is NCI funding. Program discoveries resulted in 506 publications during the prior project period, of which 10% were intra-programmatic collaborations, and 19% were inter-programmatic collaborations. In addition, 271 (54%) Program publications were with external collaborators and 337 (67%) of publications were in high-impact (IF ?10, or field leading) journals. As an example, one achievement in the prior period was enormous strengthening of bioinformatics via recruitment. Scientifically, studies revealed how a viral oncogene exploits cell machinery to induce cell cycling and simultaneously block an anti-viral immune response. Additionally, new insights into the metabolic dependencies of stem cell self- renewal and differentiation informed how such dependencies may provide a permissive environment for tumorigenesis in the presence of pre-disposing genetic mutations. ERGR investigators cultivate a collegial environment with many structured opportunities to exchange ideas, research findings, and scientific discussions amongst Program faculty, postdocs, and students. These interactions help establish valuable collaborations that raise the quality of Program science and inspire interest in cancer-related problems. An ERGR Program guiding principle is to foster the discovery of fundamental biological processes whose alterations may contribute to cancer development and progression, which supports the ultimate JCCC goal of defeating this dreaded disease.

View original record on NIH RePORTER →